- Home
- ZYME vs OLO Comparison
ZYME vs OLO Comparison
Compare ZYME & OLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- OLO
- Stock Information
- Founded
- ZYME 2003
- OLO 2005
- Country
- ZYME United States
- OLO United States
- Employees
- ZYME N/A
- OLO N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- OLO Major Banks
- Sector
- ZYME Health Care
- OLO Finance
- Exchange
- ZYME Nasdaq
- OLO Nasdaq
- Market Cap
- ZYME 867.6M
- OLO 1.0B
- IPO Year
- ZYME 2017
- OLO 2021
- Fundamental
- Price
- ZYME $13.30
- OLO $10.12
- Analyst Decision
- ZYME Buy
- OLO Buy
- Analyst Count
- ZYME 7
- OLO 3
- Target Price
- ZYME $19.50
- OLO $10.17
- AVG Volume (30 Days)
- ZYME 494.5K
- OLO 4.7M
- Earning Date
- ZYME 07-31-2025
- OLO 07-30-2025
- Dividend Yield
- ZYME N/A
- OLO N/A
- EPS Growth
- ZYME N/A
- OLO N/A
- EPS
- ZYME N/A
- OLO 0.01
- Revenue
- ZYME $93,384,000.00
- OLO $299,107,000.00
- Revenue This Year
- ZYME $44.71
- OLO $20.21
- Revenue Next Year
- ZYME $34.57
- OLO $17.90
- P/E Ratio
- ZYME N/A
- OLO $946.08
- Revenue Growth
- ZYME 85.05
- OLO 23.31
- 52 Week Low
- ZYME $9.03
- OLO $4.32
- 52 Week High
- ZYME $17.70
- OLO $10.15
- Technical
- Relative Strength Index (RSI)
- ZYME 61.39
- OLO 75.49
- Support Level
- ZYME $12.75
- OLO $8.50
- Resistance Level
- ZYME $13.80
- OLO $10.15
- Average True Range (ATR)
- ZYME 0.42
- OLO 0.20
- MACD
- ZYME 0.07
- OLO 0.11
- Stochastic Oscillator
- ZYME 79.88
- OLO 98.21
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.